MA
Veradermics, Incorporated
MANE · NYSE
$109.58 +2.65% (+$2.83)
1M +8.42%
Piotroski F-Score Weak
3/9Valuation
-
N/A PEG N/A
P/E N/A
P/FFO N/A
Growth
-
N/A FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
-
N/A ROA N/A
ROIC N/A
Asset turnover N/A
Debt
-
N/A Int. coverage N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Stability
59 /100
Moderate Beta 1.23x
Profitable years N/A
Rev. volatility N/A
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o MANE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Reid Waldman
Employees
37
Headquarters
New Haven
Prihajajoči dogodki
10 NOV.
Earnings
Upcoming earnings report